Cost-Effectiveness and Budget Impact Analysis of Primary Screening With Human Papillomavirus Test With Genotyping in Argentina
- 1 December 2021
- journal article
- research article
- Published by Elsevier in Value in Health Regional Issues
- Vol. 26, 160-168
Abstract
No abstract availableKeywords
This publication has 51 references indexed in Scilit:
- Human papillomavirus testing for the detection of high-grade cervical intraepithelial neoplasia and cancer: final results of the POBASCAM randomised controlled trialThe Lancet Oncology, 2012
- Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA studyThe Lancet Oncology, 2011
- Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trialThe Lancet Oncology, 2010
- Cost Effectiveness in Low- and Middle-Income CountriesPharmacoEconomics, 2009
- Reducing the burden of glandular carcinomas of the uterine cervixAmerican Journal of Obstetrics and Gynecology, 2007
- High-risk HPV type-specific clearance rates in cervical screeningBritish Journal of Cancer, 2007
- The Elevated 10-Year Risk of Cervical Precancer and Cancer in Women With Human Papillomavirus (HPV) Type 16 or 18 and the Possible Utility of Type-Specific HPV Testing in Clinical PracticeJNCI: Journal of the National Cancer Institute, 2005
- Prevalence of Human Papillomavirus Infection Among Women in Concordia, Argentina:Sexually Transmitted Diseases, 2003
- Inclusion of HPV testing in routine cervical cancer screening for women above 29 years in Germany: results for 8466 patientsBritish Journal of Cancer, 2003
- Missed Opportunities for Cervical Cancer Screening of HMO Members Developing Invasive Cervical Cancer (ICC)Gynecologic Oncology, 1998